Allergan and Editas Report First Patient Dosing in P-I/II BRILLIANCE Study with AGN-151587 (EDIT-101) to Treat LCA10

Allergan and Editas Report First Patient Dosing in P-I/II BRILLIANCE Study with AGN-151587 (EDIT-101) to Treat LCA10

Shots:

  • The P-I/II study will assess the safety & efficacy of AGN-151587 (subretinal injection) in ~18 patients with Leber congenital amaurosis 10. The patients enrolled are both adult & pediatric patients (aged 3-17yrs.)
  • The first patients dosing in BRILLIANCE study marks a significant milestone toward delivering the CRISPR medicines, treating the devastating LCA10
  • AGN-151587 (EDIT-101) is a CRISPR-based investigational therapy, intended to treat LCA10 and is administered via a subretinal injection to deliver the gene-editing machinery directly to photoreceptor cells

Click here ­to­ read full press release/ article | Ref: Editas | Image: Pharma Advancement